Adams R G, Brain E G, Branch C L, Guest A W, Harrington F P, Mizen L, Neale J E, Pearson M J, Simpson I N, Smulders H
SmithKline Beecham Pharmaceuticals, Research Division, Betchworth, Surrey, U.K.
J Antibiot (Tokyo). 1995 May;48(5):417-24. doi: 10.7164/antibiotics.48.417.
(6R,7R)-7-[2-(2-Amino-4-thiazolyl)-2-[(Z)-[(S)-carboxy(3,4- dihydroxyphenyl)methyl]oxyimino]acetamido]-3-(1-methylaminopyri dinium-4-thiomethyl)ceph-3-em-4-carboxylate sodium salt (BRL 57342, 1f) combines excellent in vitro antibacterial potency against Gram-positive and Gram-negative bacteria, including P. aeruginosa and Acinetobacter spp., with excellent stability to extended spectrum beta-lactamases. This potency is reflected in in vivo efficacy studies.
(6R,7R)-7-[2-(2-氨基-4-噻唑基)-2-[(Z)-[(S)-羧基(3,4-二羟基苯基)甲基]氧亚氨基]乙酰胺基]-3-(1-甲基氨基吡啶-4-硫甲基)头孢-3-烯-4-羧酸钠盐(BRL 57342,1f)对革兰氏阳性菌和革兰氏阴性菌,包括铜绿假单胞菌和不动杆菌属,具有优异的体外抗菌效力,并且对超广谱β-内酰胺酶具有出色的稳定性。这种效力在体内疗效研究中得到了体现。